Alnylam Pharmaceuticals (ALNY) Current Deferred Tax Assets (2009 - 2010)
Alnylam Pharmaceuticals' (ALNY) quarterly Current Deferred Tax Assets came in at $1.9 million in Q3 2010, little changed on a QoQ basis from $1.9 million in Q2 2010.
Alnylam Pharmaceuticals (ALNY) Current Deferred Tax Assets (2009 - 2010) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 2 years of Current Deferred Tax Assets data on file, last reported at $1.9 million in Q3 2010.
- Quarterly Current Deferred Tax Assets changed N/A year-over-year to $1.9 million in Q3 2010, while the trailing twelve-month figure through Sep 2010 was $1.9 million (changed N/A YoY) and the FY2009 annual result came in at $1.9 million, changed N/A from the prior year.
- Current Deferred Tax Assets steadied at $1.9 million in Q3 2010, from $1.9 million in the prior quarter.
- In the past five years, Current Deferred Tax Assets ranged from a high of $1.9 million in Q3 2010 to a low of $1.9 million in Q4 2009.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2010 | 1.94 Mn |
| Sep 30, 2010 | 1.94 Mn |
| Jun 30, 2010 | 1.94 Mn |
| Jun 30, 2010 | 1.94 Mn |
| Dec 31, 2009 | 1.94 Mn |
| Dec 31, 2009 | 1.94 Mn |